Intuitive Surgical Inc. (ISRG)
ISRG (NASDAQ:Health Services)
$510.00
+0.39
+0.08%
Today's Range: 508.51 - 516.07 |
ISRG Avg Daily Volume: 357,500
| Last Update: 06/19/13 - 4:00 PM EDT |
| Volume: 279,316 |
| YTD Performance: 1.83%
|
| Open: $510.50 |
| Previous Close: $509.61 |
| 52 Week Range: $455.18 -
$585.67 |
| Oustanding Shares: 40,161,022 |
| Market Cap: 20,053,201,505 |
6-Month Chart
TheStreet Ratings Grade for ISRG
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
10 |
10 |
10 |
10 |
| Moderate Buy |
1 |
1 |
1 |
1 |
| Hold |
2 |
3 |
3 |
3 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
1 |
1 |
1 |
0 |
| Mean Rec. |
1.64 |
1.73 |
1.73 |
1.50 |
| Latest Dividend: |
0.00 |
| Latest Dividend Yield: |
0.00% |
| Dividend Ex-Date: |
07/01/03 |
| Price Earnings Ratio: |
29.30 |
|
| Price Earnings Comparisons: |
| ISRG |
Sector Avg. |
S&P 500 |
| 29.30 |
29.30 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
8.68%
|
-4.15%
|
46.72%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
24.00 |
1.07 |
0.27 |
| Net Income |
32.60 |
1.82 |
0.41 |
| EPS |
29.70 |
1.72 |
0.39 |
| Earnings for ISRG: |
| EBITDA |
0.97B |
| Revenue |
2.18B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$4.32 |
$4.24 |
$17.94 |
$20.81 |
| Number of Analysts |
12 |
11 |
11 |
12 |
| High Estimate |
$4.51 |
$4.50 |
$18.50 |
$21.51 |
| Low Estimate |
$4.20 |
$3.96 |
$17.58 |
$20.24 |
| Prior Year |
$3.75 |
$4.46 |
$15.98 |
$17.94 |
| Growth Rate (Year over Year) |
15.16% |
-4.87% |
12.27% |
15.98% |
| May 09, 2013 | 4:22 PM EDT
It was good to see, if only briefly.
| Apr 18, 2013 | 12:00 PM EDT
There are plenty of solid earnings trades to choose from over the next day or so.
| Apr 15, 2013 | 1:00 PM EDT
Don't try to grab a trade ahead of earnings.
| Mar 05, 2013 | 5:00 PM EST
The momentum favorite gets slammed on news of an FDA investigation.
Mar 01, 2013 | 7:24 AM EST
ISRG was upgraded from Hold to Buy, Cantor Fitzgerald said. $575 price target. Stock has overreactd to news of the FDA probe.
Feb 22, 2013 | 7:55 AM EST
ISRG was upgraded to Buy, Goldman Sachs said. $715 price target. Fundamentals appear to be improving.
| Jan 23, 2013 | 6:30 PM EST
There continues to be solid sector rotation, and you have to obey the price action above all else.
Jan 23, 2013 | 8:15 AM EST
Shares of ISRG now seen reaching $625, according to Lazard Capital Markets. Estimates also increased, as the company is seeing higher g...
| Jan 22, 2013 | 10:28 AM EST
Sometimes you can catch them using price targets to hedge their ratings.
Jan 20, 2013 | 6:00 PM EST
Contributor Ken Shreve takes a look at upcoming data and some key earnings reports in a shortened week of trading.
